background: hairy cell leukemia (hcl) is a chronic b-cell lymphoid leukemia characterized by pancytopenia, splenomegaly, myelofibrosis and the presence in peripheral blood, bone marrow and spleen of atypical lymphoid cells with a hairy aspect. the study aims to evaluate a group of patients with hairy cell leukemia, hospitalized in the clinic of hematology and oncology, kermanshah, iran, on a pe...

BACKGROUND/AIMS We conducted a case-control study to investigate the efficacy of interferon-alpha (IFN-alpha) and ribavirin combination therapy for patients with chronic hepatitis C and B virus (HCV/HBV) coinfection and to elucidate the interaction of these two viruses. METHODS Forty-two chronic HCV/HBV-coinfected patients (29 IFN-naive, 13 IFN-relapsed) and 84 HCV-monoinfected controls, matc...

daily. Patients receiving alisporivir as IFN-free treatment who achieved undetectable HCV–RNA levels (below 25 IU/mL) at week 4 continued with initial treatment. Patients with detectable HCV–RNA levels were given add-on IFN and continued with ALV plus PR triple therapy from week 6 to week 24. Dr. Pawlotsky reported a greater than 3 log reduction in mean HCV–RNA levels over the first 4 weeks wit...

Hepatitis C virus (HCV) infection is a major cause of morbidity and mortality in the HIV co-infected population. Interferon-alpha (IFN-α) remains a major component of anti-HCV therapy despite its deleterious effects on the immune system. Furthermore, IFN-α was recently shown to diminish the size of the latent HIV reservoir. The objectives of this study were to monitor the impact of IFN-α on T c...

The risk of Hepatocellular carcinoma (HCC) is high in HCV-infected patients who have biochemically and histologically active chronic hepatitis. To observe the long prognosis of Chronic Hepatitis C (CHC) patients with stage 3 fibrosis (F3), 55 CHC patients after initial Interferon (IFN) therapy were followed up for up to 12 years (average 9.8 +/- 2.3 years). According to the annual average alani...

Infection with the hepatitis C virus (HCV) is a major cause of chronic liver diseases and hepatocellular carcinoma worldwide, and thus represents a significant public health problem. The type I interferon (IFN), IFNα, has been successful in treating HCV-infected patients, but current IFN-based treatment regimens for HCV have suboptimal efficacy, and relatively little is known about why IFN ther...

A 42-year-old male patient, who had been on colchicine therapy for familial mediterranean fever admitted with dyspnea on exertion. He had a history of interferon-alpha (IFN-alpha) administration. The chest X-ray showed diffuse distribution of reticulonodular opacities in both lungs. A computerized tomography scan of the lungs revealed mediastinal and bilateral hilar lymphadenopathies, transluce...

Background & Aims: This study aimed to identify host single nucleotide polymorphisms (SNPs) that are associated with the efficacy of interferon (IFN) therapy in patients with chronic hepatitis C. Methods: We examined whether 116 tagging-SNPs from 13 genes which are involved in Type I IFN signaling associate with the outcome of IFN therapy in Japanese case-control groups; the study included 468 ...

(IFN-␣) can induce molecular remission in chronic myelogeneous leukemia (CML). 1 This may indicate that it could be opportune to prolong IFN treatment for a long time; however, albeit rarely, this therapeutic strategy can produce unusual complications. 2 In this regard, we believe it useful to report the development of pericardial effusion in a 28-year-old Ph-positive CML patient during therapy...